PHARMACOLOGY OF NOVAL CANNABINOIDS

  • SUMITHA S. K. Department of Pharmacy Practice, J. K. K. Nattraja College of Pharmacy, Erode, India
  • VEENA S. PATTAMMADY J. K. K. Nattraja College of Pharmacy, Erode, India
  • R. SAMBATHKUMAR Department of Pharmaceutics, J. K. K. Nattraja College of Pharmacy, Erode, India

Abstract

Cannabis is a plant rich in various compounds that have a variety of impacts on the physiology of humans and the effects of these metabolites have a significant role in managing a variety of clinical diseases. A substantial increase in the use of SC (synthetic cannabinoids) had seen in the last few years especially infrequent cannabis users. The SCs will generate psychoactive effects that were similar to cannabis. However, the composition and pharmacological characteristics of these drugs make them possibly hazardous.


Like all drugs, cannabis’ pharmacokinetics depends on the route of administration. Several studies showed that the bioavailability is less in oral administration when compared to inhalation. The main reason for this decrease in oral bioavailability is that cannabinoids undergo the first-pass metabolism before entering into the systemic circulation whereas in inhalation, it enters the circulation directly through the lungs.


Cannabis sativa is a psychoactive plant that contains more than 500 components of which 104 cannabinoids had been identified. Of these, 2 components such as Δ9-THC (Δ9-tetrahydrocannabinol) and CBD (cannabidol) were under the scientific investigation. Δ9-THC is the primary cannabinoid which was responsible for the consequences of psychotrophy. The potency of cannabis is assessed based on the THC concentration of a sample that is the main psychoactive cannabinoid in cannabis. The adverse effects are in direct relation to the concentration of THC in the product after regular cannabis use. It can be assumed that several cannabinoids will find their way into the pharmacies from preclinical research within a century.

Keywords: Cannabis sativa, Synthetic cannabinoids, Δ9-THC, CBD, Psychoactive effects

Downloads

Download data is not yet available.

References

1. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-7.
2. Ahmed SA, Ross SA, Slade D, Radwan MM, Khan IA, ElSohly MA. Structure determination and absolute configuration of cannabichromanone derivatives from high potency cannabis sativa. Tetrahedron Lett 2008;49:6050-3.
3. Pertwee RG. The central neuropharmacology of psychotropic cannabinoids. Pharmacother 1987;36:189-261.
4. Pertwee RG. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Pharm Pharmacol Comm 1997;3:539-45.
5. Svizenskaa I, Dubovya P, Sulcovab A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures-a short review. Pharmacol Biochem Behav 2008;90:501-11.
6. Pertwee RG. Sites and mechanisms of action. In: Grotenhermen F, Russo E. editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press 2002;4:73–88.
7. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. HU-308: a specific agonist for CB, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999;96:14228-33.
8. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-31.
9. Sanchez C, de Ceballos ML, del Pulgar TG, Rueda D, Corbacho C, Velasco G, et al. Inhibition of glioma growth in vivo by selective activation of the CB cannabinoid receptor. Cancer Res 2001;61:5784–9.
10. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946–9.
11. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 2002;99:8400–5.
12. Blackmer T, Larsen EC, Bartleson C, Kowalchyk JA, Yoon E, Preininger AM, et al. G protein beta gamma directly regulates SNARE protein fusion machinery for secretory granule exocytosis. Nat Neurosci 2005;8:421-5.
13. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002;66:101-21.
14. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006;318:304-11.
15. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: ?9-tetrahydrocannabinol, cannabidiol and ?9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215.
16. Cabral GA, Staab A. Effects on the immune system. Handb Exp Pharmacol 2005;168:385-423.
17. Castillo A, Tolon MR, Fernandez Ruiz J, Romero J, Martinez Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Neurobiol Dis 2010;37:434-40.
18. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci 2006;103:7895-900.
19. Pertwee RG, Howlett AC, Abood ME, Alexander PH, Di Marzo V, Elphick MR, et al. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010;62:588-631.
20. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4:1770-804.
21. Grotenhermen, Franjo. Pharmacokinetics and pharmacodynamics of cannabinoids. Anesthesiology 1997;86: 24-33.
22. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992;16:276-82.
23. Goulle J, Saussereau E, Lacroix C. Delta-9-tetrahydrocannabinol pharmacokinetics. Ann Pharm Francaises 2008;66:232-4.
24. Grotenhermen, Franjo. Pharmacokinetics and pharmacodynamics of cannabinoids. Anesthesiology 1997;86:24-33.
25. Mcpartland JM, Russo EB. Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Therapeutics 2001;14:103-32.
26. Sharma P, Murthy P, Bharath MMS. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry 2012;7:149-56.
27. Abramovici H. Information for health care professionals: cannabis (marihuana, marijuana) and the cannabinoids. Health Canada 2013;1:111-8.
28. Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EE, et al. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit 2005;27:799-810.
29. Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals 2012;5:529-52.
30. Bachs L, Morland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001;124:200–3.
31. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001;103:2805–9.
32. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001;58:909–15.
33. Pope HG Jr. Cannabis, cognition, and residual confounding. JAMA 2002;287:1123–31.
34. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002;287:1123–31.
35. Lyketsos CG, Garrett E, Liang KY, Anthony JC. Cannabis use and cognitive decline in persons under 65 y of age. Am J Epidemiol 1999;149:794–800.
36. Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 9-to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 1998;20:293–306.
37. Solowij N, Grenyer BFS. Long term effects of cannabis on psyche and cognition. In: Grotenhermen F, Russo E. editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press 2002;2:299–312.
38. Nunez LA, Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatr Scand 2002;105:173–8.
39. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol 2003;2:291–8.
40. Perez Reyes M. The psychologic and physiologic effects of active cannabinoids. In: Nahas G, Sutin KM, Harvey DJ, Agurell S. Marihuana and medicine. Totowa, NJ: Humana Press 1999;3:245–52.
41. Tashkin DP, Levisman JA, Abbasi AS, Shapiro BJ, Ellis NM. Short term effects of smoked marihuana on left ventricular function in man. Chest 1977;72:20–6.
42. Shubhi R, Mohammed SQ, Deepak O. In vitro study of anti-inflammatory and antioxidant activity of some medicinal plants and their interrelationship. Asian J Pharm Clin Res 2018;4:195-202.
43. Neha C, Umar F, Mohammad AK. Efficacy of medicinal plants against human pathogens isolated from western himalayas of himachal pradesh. Asian J Pharm Clin Res 2017;9:353-7.
44. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001;98:3662–5.
45. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002;301:1020–4.
46. De Petrocellis L, Melck D, Bisogno T, Milone A, Di Marzo V. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience 1999;92:377–87.
47. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002;68:619–31.
48. Al-Hayani A, Wease KN, Ross RA, Pertwee RG, Davies SN. The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. Neuropharmacology 2001;41:1000–5.
49. Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001;298:7–14.
50. Di Marzo V. Endocannabinoids‘ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1998;1392:153–75.
51. Dinh TP, Freund TF, Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 2002;121:149–58.
52. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo Pena MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 1999;96:12198–203.
53. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822–5.
54. Roques B. Problems caused by the danger of drugs. Report of professor bernhard roques to the health minister. Paris 1998;3:52-60.
55. Georgotas A, Zeidenberg P. Observations on the effects of four weeks of heavy marihuana smoking on group interaction and individual behavior. Compr Psychiatry 1979;20:427–32.
56. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the national comorbidity survey. Exp Clin Psychopharmacol 1994;2:244–68.
57. McPartland JM, Russo EB. Cannabis and Cannabis Extracts: greater than the sum of their parts? J Cannabis Ther 2001;1:103–32.
58. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986;38:1–20.
59. Rubino T, Vigano D, Massi P, Parolaro D. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940. J Neurochem 2000;75:2080–6.
60. Georgotas A, Zeidenberg P. Observations on the effects of four weeks of heavy marihuana smoking on group interaction and individual behavior. Compr Psychiatry 1979;20:427–32.
61. Szabo B, Nordheim U, Niederhoffer N. Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther 2001;297:819–26.
62. Mechoulam R, Shohami E, Fride E, Bab I. The ubiquitous role of endocannabinoids in physiological processes: examples in neuroprotection, feeding and bone formation. First European Workshop on Cannabinoid Research. Madrid (Spain) 2003;23:56-74.
63. Underner M, Urban T, Perriot J. Cannabis smoking and lung cancer. Int J Appl Pharm 2014;31:488–98.
64. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 1998;95:8375–80.
65. Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989;249:444–9.
66. McCallum RW, Soykan I, Sridhar KR, Ricci DA, Lange RC, Plankey MW. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999;13:77–80.
67. Coruzzi G, Adami M, Coppelli G, Frati P, Soldani G. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol 1999;360:715–8.
68. Pate D. Glaucoma and cannabinoids. In: Grotenhermen F, Russo E. editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press 2002;67:215–24.
69. Laine K, Jarvinen K, Jarvinen T. Topically administered CB-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive rabbits. Life Sci 2003;72:837–42.
70. Romero J, Garcia Palomero E, Castro JG, Garcia Gil L, Ramos JA, Fernandez Ruiz JJ. Effects of chronic exposure to ?9 tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res 1997;46:100–8.
71. Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J, et al. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of ?9-tetrahydrocannabinol-tolerant rats. J Neurochem 2000;74:1627–35.
72. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 1976;282:221–39.
73. Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther 1975;18:287–97.
74. Wachtel SR, de Wit H. Naltrexone does not block the subjective effects of oral delta-tetrahydrocannabinol in humans. Drug Alcohol Depend 2000;59:251-60.
75. Haney M, Bisaga A, Foltin RW. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology 2003;166:77–85.
76. Dora BN, Ganga RB, Raviteja B. Cytotoxicity activity of some indian medicinal plants. Int J Curr Pharm Res 2016;4:86-8.
Statistics
116 Views | 79 Downloads
Citatons
How to Cite
S. K., S., V. S. PATTAMMADY, and R. SAMBATHKUMAR. “PHARMACOLOGY OF NOVAL CANNABINOIDS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 12, no. 1, Dec. 2019, pp. 1-5, doi:10.22159/ijpps.2020v12i1.36005.
Section
Review Article(s)